As genomic data swells beyond expectations, researchers face a dilemma over how to secure the information on people's DNA without stymying progress in the genomics revolution. In an opinion column in Nature , University of California, Berkeley Professor Steven Brenner tackles the issue and lays out a set of potential solutions.
Last week 23andMe sent a clear signal about its interest in attracting more customers to its genetic testing service, hiring board member and consumer web veteran Andy Page as president.
From the inception of the Human Genome Project in 1988 until 2012, the genomics revolution has had a total impact of nearly $1 trillion on the U.S. economy, according to a new report released Wednesday.
A new study asserts that the $14.5 billion federal tab for genomics research has paid off handsomely, with close to a trillion dollars in returns. But it didn't take long for the report to start attracting critics for the kind of math that was used by analysts at Battelle.
Nearly 70 organizations have united to form an ambitious global alliance to improve how genomic and clinical data are managed and shared.
OpGen has beefed up the technology around its whole-genome mapping system, which can be used to spot the DNA fingerprints of pathogens and other molecules.
The economist Edward Fiedler famously said "He who lives by the crystal ball soon learns to eat ground glass," a statement to whose veracity I can readily attest having written widely on the potential of genomics during my tenure on Wall Street. Read the feature >>
To translate Big Data in genomics into useful healthcare products, entrepreneurs might have roll up their sleeves an invent their own solutions like the Srinivasan brothers have.
In an ambitious effort to find more personalized treatments for cancer and other complex diseases, Oregon Health & Science University in Portland and Intel are teaming up to develop new computing technologies to map an individual's genetic profile more quickly, precisely and cost-effectively.
Later this year, the Multiple Myeloma Research Foundation and genomic software startup GenoSpace plan to launch a massive data project, called the CoMMpass study, which will follow 1,000 multiple myeloma patients over a 5-year period to help scientists understand the molecular changes underpinning the progression of the disease.